Some studies have shown that a statistically significant reduction in the risk of developing T2D in treatment with TNF inhibition, and the improvement in insulin sensitivity in during prolonged treatment with the anti-TNF-α antibody infliximab in insulin resistant subjects (61). This evidence concerns the gene INS and type 2 diabetes mellitus.